A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Hands-on biotech training delivers credentials, research projects, and real lab access for San Antonio students—fueling ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

State officials on Monday have announced renovation plans at SUNY Upstate Medical Center’s CNY Biotech Accelerator as well as nearly $3 million in funding to help advance the ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.